DNA vaccine placebo

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

CompletedNCT00801697

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2009-02-28End: 2015-04-30Updated: 2021-10-14

Phase 2

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

TerminatedNCT00865566

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2009-05-31End: 2017-10-06Updated: 2021-10-15

Related Papers

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens2021-11-292 citations

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

New England Journal of Medicine2013-10-07578 citations

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

2012-08-0369 citations

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

2010-09-2176 citations